Hôpital Cochin

OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases

Retrieved on: 
Tuesday, March 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, European Alliance, United, United Nations, Asthma, AAP, Yale school, CD74, Hôpital Cochin, Trinity College Dublin, Arthritis & Rheumatology, Molecular medicine, Cancer, University, Publication, Medical school, ASCI, Prognosis, Trinity, Pathology, Diagnosis, Public health, Trinity College, Arthritis, Physiology, Biomarker, Global Health, Nephritis, Society, EULAR, Inflammatory bowel disease, Physician, Pharmaceutical industry

OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.

Key Points: 
  • OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.
  • ON104 is a monoclonal antibody targeting the oxidized isoform of the macrophage migration inhibitory factor (oxMIF) for the treatment of chronic inflammatory diseases.
  • His research focuses on arthritis and other inflammatory rheumatic diseases, precision medicine, and the management of complex diseases.
  • Dr. Freissmuth is an inaugural member of OncoOne’s scientific advisory board, where he continues to support the development of the company’s pipeline of biotherapeutics.

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Retrieved on: 
Wednesday, November 1, 2023
T helper 17 cell, Psoriasis, Medical research, Pulmonary fibrosis, Publication, Scleroderma, Preprint, Immunodeficiency, TGF, RNA, Cytokine, Fibrosis, GVHD, Research, Inflammation, INSERM, ITK, Induction, MMP2, Hôpital Cochin, Systemic, Clinical trial, Asthma, Atopic dermatitis, Cancer, IL-5, Memorial Sloan Kettering Cancer Center, Lymphoma, Chronic obstructive pulmonary disease, COPD, Enteropathy-associated T-cell lymphoma, Lupus, Extractive metallurgy, Vaccine, Rheumatology, Corvus, T helper cell

BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. Corvus’ ITK inhibitors include soquelitinib (formerly known as CPI-818), which was used in the preclinical studies and is currently in clinical trials for oncology indications, and several next-generation molecules that are being optimized for use in a variety of inflammatory and immune disease indications.

Key Points: 
  • “Our research on soquelitinib and selective ITK inhibition is uncovering valuable new information about immune function and the role of ITK in different diseases,” said James Rosenbaum, M.D., senior vice president of research at Corvus.
  • “The activity of soquelitinib in various inflammatory and immune disease models highlights the essential role of ITK in multiple T cell functions.
  • The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
  • With this new publication, we further demonstrate the wide range of opportunities for ITK inhibition across specific indications with ongoing patient needs for new therapies.

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

Retrieved on: 
Friday, June 9, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, VRTX, Life, Observational study, Vertex, German, Quality of life, IA, Mutation, Cystic fibrosis, Medicine, ECFS, CFTR, Assistance, Cystic fibrosis transmembrane conductance regulator, European, Elexacaftor/tezacaftor/ivacaftor, Ageing, Hôpital Cochin, CF, Death, Conference, Safety, Vertex Pharmaceuticals, Pharmaceutical industry, Birth control

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 12 scientific abstracts on the company’s portfolio of cystic fibrosis (CF) medicines were presented at this year’s European Cystic Fibrosis Society's (ECFS) 46th European Cystic Fibrosis Conference held June 7-10, 2023, in Vienna, Austria.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 12 scientific abstracts on the company’s portfolio of cystic fibrosis (CF) medicines were presented at this year’s European Cystic Fibrosis Society's (ECFS) 46th European Cystic Fibrosis Conference held June 7-10, 2023, in Vienna, Austria.
  • Together, the data presented show the long-term benefits of treatment with CFTR modulators as well as the importance of treating the underlying cause of CF as early in life as possible.
  • Key data presented at this year’s conference are highlighted below.
  • “The data on TRIKAFTA in particular demonstrate that this medicine improves lung function sustainably and in a real-world setting.

Mark Scott Awarded the Elsevier and Institut Cochin Innovation Award 2019

Retrieved on: 
Tuesday, July 2, 2019
Philosophy, Philosophers, Articles, Hôpital Cochin, Elsevier, Paris Descartes University, René Descartes

PARIS, July 2, 2019 /PRNewswire/ --The Institut Cochin, Paris Descartes Foundation and Elsevier , the information analytics business specializing in science and health, today awarded Mark Scott the third Elsevier-Institut Cochin Innovation prize for his work on the development of chemicalmodulators of tumorsuppressor PTEN.

Key Points: 
  • PARIS, July 2, 2019 /PRNewswire/ --The Institut Cochin, Paris Descartes Foundation and Elsevier , the information analytics business specializing in science and health, today awarded Mark Scott the third Elsevier-Institut Cochin Innovation prize for his work on the development of chemicalmodulators of tumorsuppressor PTEN.
  • Frdric Dardel, the President of Paris Descartes University, presented the award, which symbolizes the commitments of Elsevier to the Paris-Descartes Foundation, in the support of French research and scientific innovation.
  • "We are committed to making excellent research visible and in this context, I want to congratulate Dr. Mark Scott for receiving this award."
  • The location of Institut Cochin inside the Paris University Hospital Center (Cochin and Port-Royal sites) allows strong interactions between research teams and the clinical services.

Mark Scott Awarded the Elsevier and Institut Cochin Innovation Award 2019

Retrieved on: 
Tuesday, July 2, 2019
Philosophy, Philosophers, Articles, Hôpital Cochin, Elsevier, Paris Descartes University, René Descartes

PARIS, July 2, 2019 /PRNewswire/ --The Institut Cochin, Paris Descartes Foundation and Elsevier , the information analytics business specializing in science and health, today awarded Mark Scott the third Elsevier-Institut Cochin Innovation prize for his work on the development of chemicalmodulators of tumorsuppressor PTEN.

Key Points: 
  • PARIS, July 2, 2019 /PRNewswire/ --The Institut Cochin, Paris Descartes Foundation and Elsevier , the information analytics business specializing in science and health, today awarded Mark Scott the third Elsevier-Institut Cochin Innovation prize for his work on the development of chemicalmodulators of tumorsuppressor PTEN.
  • Frdric Dardel, the President of Paris Descartes University, presented the award, which symbolizes the commitments of Elsevier to the Paris-Descartes Foundation, in the support of French research and scientific innovation.
  • "We are committed to making excellent research visible and in this context, I want to congratulate Dr. Mark Scott for receiving this award."
  • The location of Institut Cochin inside the Paris University Hospital Center (Cochin and Port-Royal sites) allows strong interactions between research teams and the clinical services.